{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:01:40Z","timestamp":1791669700531,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dsx.2025.103314","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:46:00Z","timestamp":1761122760000},"page":"103314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-6024","authenticated-orcid":false,"given":"Lindsay A.","family":"Courtney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M.","family":"Pitlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Mandy","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather P.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dsx.2025.103314_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract."},{"issue":"Supplement 1","key":"10.1016\/j.dsx.2025.103314_bib2","first-page":"S181","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care."},{"key":"10.1016\/j.dsx.2025.103314_bib3","unstructured":"FDA drug shortages. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/default.cfm. [Accessed 7 July 2025]."},{"key":"10.1016\/j.dsx.2025.103314_bib4","series-title":"United States Code: Federal Food, Drug, and Cosmetic Act","first-page":"392","year":"1934"},{"key":"10.1016\/j.dsx.2025.103314_bib5","unstructured":"Drug shortages statistics. https:\/\/www.ashp.org\/drug-shortages\/shortage-resources\/drug-shortages-statistics?loginreturnUrl=SSOCheckOnly. [Accessed 15 July 2025]."},{"key":"10.1016\/j.dsx.2025.103314_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.693426","article-title":"Drug shortage: causes, impact, and mitigation strategies","volume":"12","author":"Shukar","year":"2021","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.dsx.2025.103314_bib7","first-page":"467","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages. Clin Diabetes","volume":"41","author":"Whitley","year":"2023"},{"key":"10.1016\/j.dsx.2025.103314_bib9","unstructured":"Luhby T. Ozempic, Mounjaro and hundreds of other drugs become even more expensive in 2024. CNN. Accessed April 21, 2024. https:\/\/www.cnn.com\/2024\/02\/15\/economy\/ozempic-mounjaro-drug-prices-increase\/index.html."},{"key":"10.1016\/j.dsx.2025.103314_bib10","author":"Burke"},{"key":"10.1016\/j.dsx.2025.103314_bib11","author":"Cain"},{"key":"10.1016\/j.dsx.2025.103314_bib14","unstructured":"Viercinski R., Snively D. Glucagon-like peptide-1 receptor agonists: a pharmacy perspective on insurance coverage and medication access. [Accessed June 26, 2025]."},{"key":"10.1016\/j.dsx.2025.103314_bib17","series-title":"Plainsboro, NJ: Novo nordisk","article-title":"Victoza [package insert]","year":"2010"},{"key":"10.1016\/j.dsx.2025.103314_bib18","series-title":"Plainsboro, NJ: Novo nordisk","article-title":"Saxenda [package insert]","year":"2023"},{"key":"10.1016\/j.dsx.2025.103314_bib19","series-title":"Indianapolis","year":"2020"},{"key":"10.1016\/j.dsx.2025.103314_bib20","series-title":"Plainsboro, NJ: Novo nordisk","article-title":"Ozempic [package insert]","year":"2025"},{"key":"10.1016\/j.dsx.2025.103314_bib21","series-title":"Plainsboro, NJ: Novo nordisk","article-title":"Wegovy [package insert]","year":"2025"},{"key":"10.1016\/j.dsx.2025.103314_bib22","series-title":"Indianapolis","year":"2023"},{"key":"10.1016\/j.dsx.2025.103314_bib23","series-title":"Indianapolis","year":"2025"},{"issue":"9","key":"10.1016\/j.dsx.2025.103314_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol."},{"issue":"5S","key":"10.1016\/j.dsx.2025.103314_bib25","first-page":"S1","article-title":"Kidney disease: improving global outcomes diabetes work group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.dsx.2025.103314_bib31","series-title":"Princeton, NJ: Bristol-Myers Squibb","year":"2014"},{"key":"10.1016\/j.dsx.2025.103314_bib32","series-title":"Princeton, NJ: Bristol-Myers Squibb","year":"2021"},{"key":"10.1016\/j.dsx.2025.103314_bib33","series-title":"Bridgewater, NJ: Sanofi-Aventis","year":"2016"},{"key":"10.1016\/j.dsx.2025.103314_bib34","unstructured":"Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk; 2019."},{"issue":"24","key":"10.1016\/j.dsx.2025.103314_bib26","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.dsx.2025.103314_bib27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.dsx.2025.103314_bib30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.dsx.2025.103314_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","article-title":"Trends in utilization of Glucose- and weight-lowering medications after tirzepatide approval in the United States\u202f: a population-based cohort study","volume":"178","author":"Ostrominski","year":"2025","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.dsx.2025.103314_bib47","author":"Bormel"},{"key":"10.1016\/j.dsx.2025.103314_bib48","author":"Bormel"},{"key":"10.1016\/j.dsx.2025.103314_bib49","author":"Bormel"},{"key":"10.1016\/j.dsx.2025.103314_bib58","author":"Constantino"},{"key":"10.1016\/j.dsx.2025.103314_bib59","author":"Lupkin"},{"key":"10.1016\/j.dsx.2025.103314_bib60","author":"Wingrove"},{"issue":"19","key":"10.1016\/j.dsx.2025.103314_bib67","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss","volume":"329","author":"Suran","year":"2023","journal-title":"JAMA."},{"issue":"22","key":"10.1016\/j.dsx.2025.103314_bib68","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1001\/jama.2023.16620","article-title":"As semaglutide\u2019s popularity soars, rare but serious adverse effects are emerging","volume":"330","author":"Ruder","year":"2023","journal-title":"JAMA."},{"key":"10.1016\/j.dsx.2025.103314_bib69","author":"Goodman"},{"key":"10.1016\/j.dsx.2025.103314_bib72","author":"Soni"},{"issue":"9","key":"10.1016\/j.dsx.2025.103314_bib74","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/jac5.1999","article-title":"Legal, safety, and practical considerations of compounded injectable semaglutide","volume":"7","author":"Spitery","year":"2024","journal-title":"J Am Coll Clin Pharm."},{"issue":"5","key":"10.1016\/j.dsx.2025.103314_bib75","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.japh.2023.06.017","article-title":"Administration errors of compounded semaglutide reported to a poison control center-case series","volume":"63","author":"Lambson","year":"2003","journal-title":"J Am Pharmaceut Assoc."},{"issue":"2","key":"10.1016\/j.dsx.2025.103314_bib76","first-page":"91","article-title":"Real-world observations of using compounded GLP-1 \u00b1 GIP agonists within a clinical pharmacist-managed cardiometabolic clinic","volume":"8","author":"Finks","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"10.1016\/j.dsx.2025.103314_bib77","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/dom.16162","article-title":"Weight loss and body composition after compounded semaglutide treatment in a real world setting","volume":"27","author":"Chun","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"100061","key":"10.1016\/j.dsx.2025.103314_bib78","article-title":"Compounded peptides: an obesity medicine association position statement","volume":"6","author":"Fitch","year":"2023","journal-title":"Obesity Pillars."}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125001316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:36:54Z","timestamp":1780731414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402125001316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1871402125001316"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103314","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103314"}}